Navigation Links
Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
Date:3/6/2009

Therapure will apply its expertise to the development of an innovative plasma protein resulting from LFB's research

Toronto, Canada and Les Ulis, France (PRWEB) March 6, 2009 -- Thomas Wellner, President and CEO of Therapure BioPharma Inc. and Christian Béchon, President and CEO of LFB S.A. announce that a development services contract has been concluded between Therapure Biopharma Inc. and LFB Biotechnologies, a subsidiary of LFB SA, for the development of a manufacturing method for an innovative plasma therapeutic protein.

Therapure will apply its experience and knowledge in therapeutic protein development to develop a manufacturing process to enable the large scale production of this important biologic for clinical trials. The project, which is being jointly managed by research and development teams from the two companies, is expected to yield a novel treatment for a serious illness which currently has limited treatment options.

"We are pleased that LFB Biotechnologies, a major European player in the therapeutic protein field, has selected Therapure Biopharma for this important work," said Thomas Wellner. "Our development team has extensive knowledge in the area of plasma proteins purification and manufacturing methods and we have already achieved some key milestones in this project."

"We have a strong expertise in the development and manufacture of plasma-derived medicinal products and an important R&D portfolio. We have chosen to identify partners with complementary knowledge and the skills to help us to advance some of our products," said Bernard Pelletier, strategic development program director. "We have recognized the strong technical capabilities of Therapure Biopharma in this area and we are pleased with the progress of the project to date."

About Therapure Biopharma
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma is also a specialist in therapies derived from hemoglobin, a blood protein. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com.

About LFB
LFB is a pharmaceutical group and the first French company in the biotech field. LFB is the fifth largest pharmaceutical company in plasma-derived medicinal products in the world, and the third largest laboratory supplying drugs to hospitals in France. LFB commercializes a wide range of 19 plasma-derived medicinal products, addressing more than 80 pathologies in three therapeutic fields: Immunology, Hemostasis, and Intensive Care. Each year, 500,000 patients are treated with LFB's products for chronic pathologies or for emergency cases. In the biotechnology field, LFB develops monoclonal antibodies and a line of therapeutic proteins through transgenic technology with GTC Therapeutics.

For more information, please visit www.lfb.fr.

Media Contact, Therapure Biopharma Inc.:
Alison Withey
+1 705-788-0080

Media Contact, LFB S.A.:
Sandrine Charrières, Corporate Communications Director
+33 169 827 280

# # #

Read the full story at http://www.prweb.com/releases/Therapure_Biopharma/LFB_Biotechnologies/prweb2192744.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
2. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
3. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
4. China Biopharma, Inc. Issues Corporate Information Update
5. Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update
6. Wound Management Technologies, Inc. Announces Negotiations to Acquire BioPharma Management Technologies, Inc.
7. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Best Practice Database Provides Key Findings for Biopharma Product Launch Evaluation
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed ... of its ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada ... Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that ...
(Date:7/21/2017)... MO (PRWEB) , ... July 21, 2017 , ... “Kids ... knowing how to tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive ... Time-In Toolkit, which launches on Kickstarter on Monday, July 21st. , The kit ...
(Date:7/21/2017)... ... July 21, 2017 , ... The ... offer patients improved quality of life five years after injury, according to research ... Meeting in Toronto, Ontario, Canada. The study followed patients for five years following ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... of blood and bone marrow cancer that progresses rapidly without treatment. Newly diagnosed ... to reduce the chance of reoccurrence and relapse. With such a challenging ...
(Date:7/20/2017)... New York (PRWEB) , ... July 20, 2017 ... ... has developed a telemedicine platform, in which their iMedSecure™ comes included with each ... both share encrypted live images to remote participants for real-time collaboration and immediate ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/6/2017)... division of Diplomat Specialty Infusion Group, is celebrating a decade of empowering ... celebrate its anniversary, ThriveRx recently launched a redesigned website at thriverx.diplomat.is ... to create the best user experience for consumers and health care professionals. ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 years," ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), today announced that it has reached ... holder and largest shareholder, to modify its existing credit ... to the modification, WAVI agreed to exchange its existing ...
Breaking Medicine Technology: